Semaphorin 3F (SEMA3F) influences patient survival in esophageal adenocarcinoma
View abstract on PubMed
Summary
This summary is machine-generated.Semaphorin 3F (SEMA3F) expression predicts better survival in early-stage esophageal adenocarcinoma patients. Its receptor, Neuropilin 2 (NRP2), is linked to lymph node metastasis, suggesting SEMA3F as a potential prognostic marker.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Lymph node metastasis is a critical prognostic factor in esophageal adenocarcinoma.
- Accurate markers for detecting lymph node metastasis are currently lacking.
- The SEMA3F/NRP2 axis plays roles in angiogenesis and carcinogenesis.
Purpose Of The Study
- To investigate the roles of SEMA3F and its receptor NRP2 in esophageal adenocarcinoma.
- To evaluate SEMA3F and NRP2 as potential biomarkers for lymph node metastasis and patient prognosis.
Main Methods
- Immunohistochemical evaluation of SEMA3F and NRP2 protein expression in 776 esophageal adenocarcinoma patients.
- Digital analysis of protein expression using QuPath, verified by pathologists.
- Survival analyses to correlate protein expression with patient outcomes.
Main Results
- SEMA3F positive expression correlated with lower pT and pN stages.
- NRP2 positive expression was associated with the presence of lymph node metastases.
- SEMA3F positivity predicted a favorable patient survival outcome, especially in early-stage disease.
Conclusions
- SEMA3F is an independent predictor of favorable prognosis in early-stage esophageal adenocarcinoma.
- NRP2 expression is linked to an increased risk of lymph node metastasis.
- Targeting SEMA3F pathways may offer therapeutic potential for esophageal adenocarcinoma.

